Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HTR2A | P28223 | 6/20 | 0.46 |
| ▸ | HTR2C | P28335 | 6/20 | 0.46 |
| ▸ | HTR2B | P41595 | 6/20 | 0.46 |
| ▸ | STS | P08842 | 1/20 | 0.34 |
| ▸ | PDE4B | Q07343 | 1/20 | 0.33 |
| ▸ | TACR1 | P25103 | 2/20 | 0.33 |
| ▸ | USP30 | Q70CQ3 | 1/20 | 0.33 |
| ▸ | DPP4 | P27487 | 1/20 | 0.33 |
| ▸ | KAT8 | Q9H7Z6 | 2/20 | 0.33 |
| ▸ | KAT6A | Q92794 | 1/20 | 0.33 |
| ▸ | RORC | P51449 | 1/20 | 0.32 |
| ▸ | NR1H2 | P55055 | 1/20 | 0.32 |
| ▸ | KAT5 | Q92993 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4473912 | 1.00 | HTR2A (0.46) | HTR2AHTR2CHTR2BSTSPDE4B | |
| SCHEMBL4483372 | 0.86 | HTR2A (0.51) | HTR2AHTR2CHTR2BDPP4 | |
| SCHEMBL5576797 | 0.86 | HTR2A (0.45) | HTR2AHTR2CHTR2BDPP4 | |
| SCHEMBL4467073 | 0.81 | HTR2A (0.56) | HTR2AHTR2CHTR2BSTSPDE4B | |
| SCHEMBL4467177 | 0.81 | HTR2A (0.56) | HTR2AHTR2CHTR2BSTSPDE4B | |
| SCHEMBL4467069 | 0.81 | HTR2A (0.56) | HTR2AHTR2CHTR2BSTSPDE4B | |
| SCHEMBL13763030 | 0.79 | HTR2A (0.55) | HTR2AHTR2CHTR2B | |
| SCHEMBL13763136 | 0.79 | HTR2A (0.55) | HTR2AHTR2CHTR2B | |
| SCHEMBL13756868 | 0.73 | HTR2C (0.82) | HTR2AHTR2CHTR2B | |
| SCHEMBL4475914 | 0.73 | HTR2A (0.54) | HTR2AHTR2CHTR2BSTS |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7572805-B2 | Pyrrolo(oxo)isoquinolines as 5HT ligands | BRISTOL-MYERS SQUIBB COMPANY (US) | 2009-08-11 | — | — | US | disclosed |
| US-20060014777-A1 | Pyrrolo(oxo)isoquinolines as 5HT ligands | BRISTOL-MYERS SQUIBB COMPANY | 2006-01-19 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060014777-A1 | Pyrrolo(oxo)isoquinolines as 5HT ligands | HTR2B, OPRD1, HTR1B | HTR2A 31/4885HTR2C 17/4885HTR2B 1/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.